Holen Sie sich die Stockscreener-App
30.68
1.41%
-0.44
Handel nachbörslich:
30.50
-0.18
-0.59%
Schlusskurs vom Vortag:
$31.12
Offen:
$30.8
24-Stunden-Volumen:
1.06M
Relative Volume:
0.71
Marktkapitalisierung:
$2.93B
Einnahmen:
$305.00K
Nettoeinkommen (Verlust:
$-328.98M
KGV:
-7.1931
EPS:
-4.2652
Netto-Cashflow:
$-309.60M
1W Leistung:
-3.76%
1M Leistung:
+0.82%
6M Leistung:
+101.44%
1J Leistung:
+55.26%
1-Tages-Spanne:
$30.35
$31.54
1-Wochen-Bereich:
$30.35
$31.89
52-Wochen-Spanne:
$9.90
$34.04
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
30.68 | 2.97B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Bestätigt | Wedbush | Outperform |
| 2025-12-03 | Eingeleitet | William Blair | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan
What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Viridian Therapeutics Earnings Notes - Trefis
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com
Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus
FDA grants priority review for Viridian’s thyroid eye disease drug - Investing.com
Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com
Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
Will Viridian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Retail & High Win Rate Trade Tips - Улправда
Published on: 2025-12-20 23:42:03 - Улправда
Will Viridian Therapeutics Inc. stock deliver consistent dividendsGlobal Markets & Weekly High Return Stock Forecasts - ulpravda.ru
FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN) - Sahm
Aug Action: How geopolitical tensions affect Viridian Therapeutics Inc. stock2025 Support & Resistance & Community Verified Trade Signals - Улправда
Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда
Why Viridian Therapeutics Inc. (1S1) stock gets analyst attentionMarket Trend Summary & Weekly Breakout Watchlists - DonanımHaber
Published on: 2025-12-19 16:37:51 - Улправда
Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Fed Watch: Will Viridian Therapeutics Inc. stock attract more institutional investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock By Investing.com - Investing.com Canada
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Trends & Smart Money Movement Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail
Viridian Therapeutics stock reaches 52-week high at 33.67 USD By Investing.com - Investing.com Australia
Viridian Therapeutics stock reaches 52-week high at 33.67 USD - Investing.com India
Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts - ts2.tech
Viridian Therapeutics (VRDN) Sees 5% Stock Increase - GuruFocus
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week HighShould You Buy? - MarketBeat
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
Understanding Momentum Shifts in (VRDN) - Stock Traders Daily
Maverick Capital Ltd. Grows Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. $VRDN Shares Sold by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Has $6.77 Million Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Velan Capital Investment Management LP Makes New $1.21 Million Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Wedbush - MarketBeat
Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating - marketscreener.com
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):